LARIMAR THERAPEUTICS, INC. Income (Loss) from Continuing Operations before Income Taxes, Domestic
LARIMAR THERAPEUTICS, INC. (LRMR) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$165.67 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-19.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-03-19
- LARIMAR THERAPEUTICS, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was -$165.67M.
- LARIMAR THERAPEUTICS, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was -$80.60M.
- LARIMAR THERAPEUTICS, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was -$36.95M.
- LARIMAR THERAPEUTICS, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2022 was -$35.34M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month as first filed |
|---|---|---|
| 2025-12-31 | -$165.67M 10-K · filed 2026-03-19 | |
| 2024-12-31 | -$80.60M 10-K · filed 2026-03-19 | |
| 2023-12-31 | -$36.95M 10-K · filed 2025-03-24 | |
| 2022-12-31 | -$35.34M 10-K · filed 2024-03-14 | |
| 2021-12-31 | -$50.62M 10-K · filed 2023-03-14 | |
| 2020-12-31 | -$42.61M 10-K · filed 2022-03-25 | |
| 2019-12-31 | -$23.18M 10-K · filed 2021-03-04 | -$45.20M 10-K · filed 2020-03-05 |
| 2018-12-31 | -$58.71M 10-K · filed 2020-03-05 | |
| 2017-12-31 | -$49.95M 10-K · filed 2020-03-05 | |
| 2016-12-31 | -$57.80M 10-K · filed 2019-03-14 | |
| 2015-12-31 | -$72.15M 10-K · filed 2018-03-09 | |
| 2014-12-31 | -$35.82M 10-K · filed 2017-03-10 | |
| 2013-12-31 | -$12.32M 10-K · filed 2016-03-15 | |
| 2012-12-31 | -$13.14M 10-K · filed 2015-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |